Opko Health Inc

Research Opko Health Inc (OPK) on Bullrun: market cap USD 1.11B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 1.11B.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 606.88M-USD 225.68B-USD 190.82M33.9%-0.3USD 364.41MUSD 4.00MUSD 1.27B
FY2024USD 713.14M-USD 53.22B-USD 208.50M30.6%-0.08USD 426.58MUSD 440.21MUSD 1.37B
FY2023USD 863.50M-USD 188.86B-USD 44.47M36.8%-0.25USD 95.88MUSD 9.72MUSD 1.39B
FY2022USD 1.00B-USD 328.41B-USD 119.77M28.7%-0.46USD 153.19MUSD 11.01MUSD 1.56B

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 1.11Bn/an/an/a
20252025-12-31USD 956.43Mn/an/an/a
20242024-12-31USD 987.18Mn/an/an/a
20232023-12-29USD 1.17Bn/an/an/a
20222022-12-30USD 965.86Mn/an/an/a
20212021-12-31USD 3.28Bn/an/an/a

About Opko Health Inc

OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Opko Health Inc's market cap?

Opko Health Inc's market capitalization is USD 1.11B.

What does Opko Health Inc do?

OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system.